Joint Stock Company Grindeks plans to double it’s per oral final dosage forms production capacities and to substantially advance its final dosage forms manufacturing infrastructure during the next two years. The development of the manufacturing infrastructure is one of the priorities of Grindeks.
In the framework of the project the reconstruction of the existing production buildings is planned as well as new facilities will be provided and the latest well head equipment of the pharmaceutical technologies in Western Europe will be installed. More than 5 millions lats are planned to be invested in the development of the manufacturing infrastructure.
V.Jākobsons, the Chairman of the Board of Grindeks points out: “The advancement of the manufacturing infrastructure would give a chance to increase remarkably the turnover of the output and to cope with the increasing demand for the Grindeks’ final dosage forms in Latvia and abroad, but, the main thing is, it would provide the manufacturing of the drugs which will be safer, qualitative and will meet the high standards of EU.”
Taking into account that there are no enterprises in Latvia, having the experience in designing and building pharmaceutical plants, Grindeks has weighed up many designing and building offers from foreign companies. The most cost-effective to fulfill this voluminous project was approved the offer received from LSMW, Poland. There has been an Intent Agreement of per oral final dosage forms production plant construction concluded between JSC«Grindeks and LSMW, providing that the company LSMW has been chosen for the general contractor of the construction.
It is planned to start the construction works at the second quarter of this year and to complete in year 2007. It is foreseen that the new plant will have the capacities of production of more than 2 milliards of tablets and capsules per year.
The second mainstream of the company is the development and synthesis of active pharmaceutical ingredients.
Grindeks is the key pharmaceutical manufacturer in the Baltic States, specializing at final dosage forms and active pharmaceutical ingredients production. Grindeks has representation offices in nine countries and the production export includes 37 countries. The main markets are – the Baltic States, Russia, CIS countries, Japan and USA. Company’s shares are listed on the official list at Riga Stock Exchange.
Information prepared by:
Finance and Administrative director